Sagimet Biosciences (SGMT) Operating Leases (2022)

Sagimet Biosciences' (SGMT) quarterly Operating Leases came in at $78000.0 in Q4 2022.

Sagimet Biosciences (SGMT) Operating Leases (2022) Analysis & Trends

Sagimet Biosciences' Operating Leases history runs 1 years deep, the most recent figure standing at $78000.0 for Q4 2022.

On a quarterly basis, Operating Leases changed N/A year-over-year to $78000.0 in Q4 2022; TTM through Dec 2022 was $78000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $78000.0, changed N/A from the prior year.
Operating Leases steadied at $78000.0 in Q4 2022 per SGMT's latest filing.
Across five years, Operating Leases topped out at $78000.0 in Q4 2022 and bottomed at $78000.0 in Q4 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Sagimet Biosciences	228.24 Mn	228.24 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	78,000.00